Form 4: Catalyst Pharma HR Chief Exercises RSUs

Catalyst Pharmaceuticals' Chief HR Officer, Gregg Russo, exercised restricted stock units and had shares withheld for taxes on February 17, 2026.

Summary

• Gregg Russo, Chief HR Officer of Catalyst Pharmaceuticals, Inc. (CPRX), reported transactions on February 17, 2026.
• Russo exercised 687 Restricted Stock Units (RSUs), which converted into 687 shares of common stock.
• Concurrently, 211 shares of common stock were withheld by the Registrant to satisfy applicable withholding taxes upon the vesting of the restricted common stock.
• Following these transactions, Russo beneficially owns 476 shares of common stock directly.
• Russo also beneficially owns 71,786 Restricted Stock Units directly.
• The Restricted Stock Units vest in equal tranches, 1/5th each on February 13, 2026, February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.
• The first tranche of shares was delivered on February 17, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive event, reflecting a routine compensation transaction where an executive continues to hold a significant equity stake, aligning their interests with shareholders. It is not a major market moving event.

Positives

• The exercise of Restricted Stock Units and subsequent holding of common stock by a Chief HR Officer demonstrates continued alignment of management's interests with those of shareholders.
• The significant remaining balance of 71,786 Restricted Stock Units indicates a long-term incentive for the officer to contribute to the company's success.

Negatives

• Shares were withheld to cover tax obligations, which is a standard practice for RSU vesting and not inherently negative, but it does reduce the immediate net share gain for the officer.

Future Outlook

The filing details a pre-scheduled vesting and exercise of equity compensation, which does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, such as the vesting and exercise of Restricted Stock Units, are common occurrences in publicly traded companies. These filings provide transparency into how executives manage their equity compensation and can offer insights into their long-term commitment to the company. This particular transaction is a routine event related to an executive's compensation plan.

Stakeholder Impact

• Shareholders: The transaction provides transparency regarding executive compensation and equity ownership, reinforcing alignment between management and shareholder interests through continued equity holdings.
• Employees: The vesting schedule for RSUs serves as a retention mechanism for key personnel, including the Chief HR Officer.

Next Steps

• Remaining Restricted Stock Units are scheduled to vest in equal tranches on February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.
• Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting for future tranches.

Key Dates

Keywords

Catalyst Pharmaceuticals, CPRX, Gregg Russo, Chief HR Officer, Restricted Stock Units, RSU, Insider Transaction, Form 4, Equity Compensation, Stock Vesting